The FDA declined to approve one of biotech’s most closely watched cancer drugs

The FDA declined to approve one of biotech’s most closely watched cancer drugs

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

Original Source

Read the full article at Marketwatch →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.